Latest Glp1Drugs News and Updates : Glp1Drugs updates, Glp1Drugs News , Glp1Drugs around the world

Nishadil

Washington | 22°C (clear sky)

Weight‑Loss Drugs Like Ozempic and Wegovy May Boost Male‑Pattern Hair‑Loss Risk, New Genetic Study Shows

Top story

Weight‑Loss Drugs Like Ozempic and Wegovy May Boost Male‑Pattern Hair‑Loss Risk, New Genetic Study Shows

In focus

Latest feed

Ozempic, Wegovy and the Unexpected Side Effect: Hair Loss in Men

GLP-1 Medications: Unveiling Their Transformative Power Beyond Just Weight Loss

A New Hope: How 'Obesity Drugs' Are Revolutionizing Treatment for PMOS

The Future is Here: Your GLP-1 Treatment, Tailored Just For You

Latest headlines

Why Medicaid Cuts Are Leaving Millions Without Access to GLP‑1 Weight‑Loss Meds

Why Medicaid Cuts Are Leaving Millions Without Access to GLP‑1 Weight‑Loss Meds

Do Weight‑Loss Drugs Really Cut Cancer Risk? A Cautious Look at the Evidence

Do Weight‑Loss Drugs Really Cut Cancer Risk? A Cautious Look at the Evidence

Double Standard Over GLP‑1 Drugs Hits Women Especially Hard

Double Standard Over GLP‑1 Drugs Hits Women Especially Hard

Beyond Weight Loss: Could Ozempic and Mounjaro Actually Slow Down Aging?

Beyond Weight Loss: Could Ozempic and Mounjaro Actually Slow Down Aging?

The Bizarre Case: How a Diet Soda Melted a Stomach Mass, Possibly Linked to Popular Weight-Loss Drugs

The Bizarre Case: How a Diet Soda Melted a Stomach Mass, Possibly Linked to Popular Weight-Loss Drugs

Navigating Love and GLP-1s: The New Era of Dating

Navigating Love and GLP-1s: The New Era of Dating

Nestlé’s Bold Move: Banning All Artificial Food Colourings by 2026

Nestlé’s Bold Move: Banning All Artificial Food Colourings by 2026

The GLP-1 Revolution: A Budgetary Tightrope for Medicare and Medicaid

The GLP-1 Revolution: A Budgetary Tightrope for Medicare and Medicaid

The GLP-1 Revolution: A Financial Tightrope for Medicare and Medicaid

The GLP-1 Revolution: A Financial Tightrope for Medicare and Medicaid

Medicare's Landmark Shift: Finally Covering Ozempic-Style Drugs for Cardiovascular Health

Medicare's Landmark Shift: Finally Covering Ozempic-Style Drugs for Cardiovascular Health

The Street's Latest Takes: Wall Street's Tuesday Analyst Calls Spark Conversation

The Street's Latest Takes: Wall Street's Tuesday Analyst Calls Spark Conversation

The Next Frontier: How Pharma is Redefining GLP-1 Success Beyond the Pill

The Next Frontier: How Pharma is Redefining GLP-1 Success Beyond the Pill

Johnson & Johnson's Bold Bet: Steering Clear of GLP-1 Hype to Double Down on Oncology

Johnson & Johnson's Bold Bet: Steering Clear of GLP-1 Hype to Double Down on Oncology

The Weight of Progress: Employers Grapple with GLP-1 Costs and Coverage

The Weight of Progress: Employers Grapple with GLP-1 Costs and Coverage

Dexcom G7 CGM Shows Promise for Better Blood‑Sugar Control in Type 2 Diabetes

Dexcom G7 CGM Shows Promise for Better Blood‑Sugar Control in Type 2 Diabetes

Dexcom’s New G7 CGM Shows Real‑World Benefits for Type 2 Diabetes

Dexcom’s New G7 CGM Shows Real‑World Benefits for Type 2 Diabetes

Mayim Bialik's GLP-1 Ordeal: A Candid Look at Severe Side Effects After One Shot

Mayim Bialik's GLP-1 Ordeal: A Candid Look at Severe Side Effects After One Shot

Alkyl Amines Chemicals: Riding the GLP-1 Wave Towards a Pharmaceutical Future

Alkyl Amines Chemicals: Riding the GLP-1 Wave Towards a Pharmaceutical Future

A Closer Look: Are Popular Weight-Loss Drugs Linked to a Rare Eye Condition?

A Closer Look: Are Popular Weight-Loss Drugs Linked to a Rare Eye Condition?

Beyond the Scale: Unpacking the 'Ozempic Personality' and Its Emotional Ripples

Beyond the Scale: Unpacking the 'Ozempic Personality' and Its Emotional Ripples

The Evolving Landscape of Employee Benefits

The Evolving Landscape of Employee Benefits

Beyond the Hype: India's Government Puts GLP-1 Weight Loss and Diabetes Drugs Under the Microscope

Beyond the Hype: India's Government Puts GLP-1 Weight Loss and Diabetes Drugs Under the Microscope

GLP-1 Drugs: The Unexpected Battle Against Addiction

GLP-1 Drugs: The Unexpected Battle Against Addiction

Boston's Big Bet: Weighing the Costs and Cures of New Weight Loss Drugs for City Employees

Boston's Big Bet: Weighing the Costs and Cures of New Weight Loss Drugs for City Employees

A Closer Look at GLP-1s: New Research Flags Potential Link to Sudden Sight Loss and 'Eye Stroke'

A Closer Look at GLP-1s: New Research Flags Potential Link to Sudden Sight Loss and 'Eye Stroke'

The Ozempic War is Over: What the Novo Nordisk and Hims & Hers Settlement Means for Your Access to GLP-1s

The Ozempic War is Over: What the Novo Nordisk and Hims & Hers Settlement Means for Your Access to GLP-1s

Unlocking New Hope: How Weight-Loss Medications Might Revolutionize Addiction Treatment

Unlocking New Hope: How Weight-Loss Medications Might Revolutionize Addiction Treatment

The Cost of Cures: Unpacking the Price Tag of Novo Nordisk's Breakthrough Drugs in America

The Cost of Cures: Unpacking the Price Tag of Novo Nordisk's Breakthrough Drugs in America

The Price Wars Are Coming: Ozempic & Wegovy Costs Set to Plummet

The Price Wars Are Coming: Ozempic & Wegovy Costs Set to Plummet

Why Barclays Still Sees Eli Lilly as the Undisputed Champion in the Exploding GLP-1 Arena, Even as Rivals Crowd In

Why Barclays Still Sees Eli Lilly as the Undisputed Champion in the Exploding GLP-1 Arena, Even as Rivals Crowd In

The Unseen Cost of Weight Loss? Dentists Warn of 'Ozempic Teeth'

The Unseen Cost of Weight Loss? Dentists Warn of 'Ozempic Teeth'

The 'Skinny Pen' Phenomenon: A Look at India's Weight Loss Drug Revolution

The 'Skinny Pen' Phenomenon: A Look at India's Weight Loss Drug Revolution

McDonald's Takes on Ozempic: A Glimpse into the Future of Fast Food

McDonald's Takes on Ozempic: A Glimpse into the Future of Fast Food

Navigating the New Frontier of Weight Loss: Scrutiny Mounts on Telehealth Providers

Navigating the New Frontier of Weight Loss: Scrutiny Mounts on Telehealth Providers

Hims & Hers Hits the Brakes: Generic Wegovy Plans Abandoned Amidst GLP-1 Market Shifts

Hims & Hers Hits the Brakes: Generic Wegovy Plans Abandoned Amidst GLP-1 Market Shifts

Eli Lilly's Ascendant Journey: Why Its Premium Price Tag Might Just Be Worth It

Eli Lilly's Ascendant Journey: Why Its Premium Price Tag Might Just Be Worth It

Novo Nordisk: The High-Stakes Balancing Act Between Price and Scale

Novo Nordisk: The High-Stakes Balancing Act Between Price and Scale

The Shifting Sands of US Drug Pricing: Why Big Pharma Investors are on Edge

The Shifting Sands of US Drug Pricing: Why Big Pharma Investors are on Edge

Load more